Experimental Nephrology and Transplantation Laboratory, Bellvitge Institute for Biomedical Research , Barcelona, Spain.
Lung Transplant Unit, Pulmonology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
J Infect Dis. 2021 Aug 2;224(3):526-531. doi: 10.1093/infdis/jiaa727.
Monitoring cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) is useful in predicting late-onset CMV infection after solid organ transplantation, but few data have been reported after lung transplantation (LT). CMV CMI against 2 CMV antigens (IE-1, pp65) was evaluated in 60 seropositive LT at 6-month prophylaxis withdrawal. LT with late-onset CMV infection showed significantly lower (IE-1)CMV CMI than patients without (P = .045), and was more evident in patients developing high viral loads (P = .010). (IE-1)CMV CMI independently predicted high first late-onset viral replication (odds ratio, 4.358; 95% confidence interval, 1.043-18.215). CMV-specific CMI may be useful in CMV preventive strategies after LT.
监测巨细胞病毒（CMV）特异性细胞介导免疫（CMI）有助于预测实体器官移植后晚期 CMV 感染，但肺移植（LT）后报道的数据很少。在 60 例 CMV 血清阳性 LT 患者中，在 6 个月预防性停药时评估了针对 2 种 CMV 抗原（IE-1、pp65）的 CMV CMI。与无晚期 CMV 感染的患者相比，发生晚期 CMV 感染的 LT 患者的 CMV CMI（IE-1）显著降低（P=0.045），且在发生高病毒载量的患者中更为明显（P=0.010）。CMV CMI（IE-1）可独立预测首次晚期病毒复制高（比值比，4.358；95%置信区间，1.043-18.215）。CMV 特异性 CMI 可能有助于 LT 后 CMV 的预防策略。
